Analyze this passage and answer the question. With this background, consider the Surfaxin trial (page 58-62 from Hawkins and Emanuel: Case Studies Havrix and Sufaxin Trials.pdf Case Studies Havrix and Sufaxin Trials.pdf - Alternative Formats ) in which the following arguments have been made that this clinical trial was not exploitative: "To be sure, the trial makes use of the severe wealth and health care inequalities that exist among countries and regions in the world. These differences are distressing, but there is no easy or rapid way to eliminate them. Importantly, the drug company did not create or foster these inequalities. Furthermore, the world makes use of such inequalities in other ways, for example, buying goods made at the low prices that are made possible by cheaper labor in the developing countries. It thus appears that not all uses of inequalities between countries are considered "exploitative." "There is a difference between a) studying a substance too toxic to be acceptable in the U.S. in a developing country and paying people in a developing country to accept the risk that could not be imposed on U.S. citizens and b) studying a probably useful treatment in a developing country, but not giving